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Mechanism of Oral Tolerance Induction to Therapeutic Proteins
Abstract
Oral tolerance is defined as the specific suppression of humoral and / or cellular immune responses to an
antigen by administration of the same antigen through the oral route. Due to its absence of toxicity, easy
administration, and antigen specificity, oral tolerance is a very attractive approach to prevent unwanted
immune responses that cause a variety of diseases or that complicate treatment of a disease. Many
researchers have induced oral tolerance to efficiently treat autoimmune and inflammatory diseases in
different animal models. However, clinical trials yielded limited success. Thus, understanding the
mechanisms of oral tolerance induction to therapeutic proteins is critical for paving the way for clinical
development of oral tolerance protocols. This review will summarize progress on understanding the major
underlying tolerance mechanisms and contributors, including antigen presenting cells, regulatory T cells,
cytokines, and signaling pathways. Potential applications, examples for therapeutic proteins and disease
targets, and recent developments in delivery methods are discussed.
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Abstract
Oral tolerance is defined as the specific suppression of humoral and / or cellular immune
responses to an antigen by administration of the same antigen through the oral route. Due to its
absence of toxicity, easy administration, and antigen specificity, oral tolerance is a very attractive
approach to prevent unwanted immune responses that cause a variety of diseases or that
complicate treatment of a disease. Many researchers have induced oral tolerance to efficiently treat
autoimmune and inflammatory diseases in different animal models. However, clinical trials
yielded limited success. Thus, understanding the mechanisms of oral tolerance induction to
therapeutic proteins is critical for paving the way for clinical development of oral tolerance
protocols. This review will summarize progress on understanding the major underlying tolerance
mechanisms and contributors, including antigen presenting cells, regulatory T cells, cytokines, and
signaling pathways. Potential applications, examples for therapeutic proteins and disease targets,
and recent developments in delivery methods are discussed.
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1. Introduction
The human mucosal surfaces of the gastrointestinal tract, with an area of around 300 m2, are
constantly in contact with a large variety of antigens, including dietary proteins and
constituents of commensal bacteria [1]. Approximately 30 kg of food proteins per year reach
the gut, and 1012 bacteria per g of stool colonize the human intestinal mucosa [2, 3]. Under
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such a high antigen pressure, it is natural for the gut to develop a mechanism to abrogate
potentially injurious inflammatory responses and favor a tolerogenic environment. However,
most pathogens also enter the human body through GI tract [4]. The gut immune system has
evolved a complicated and tightly regulated mechanism to suppress unwanted inflammatory
responses while at the same time protecting the body from pathogenic organisms. Generally,
there are at least three types of responses to oral antigen administration – a local secretory
IgA antibody response which protects mucus layer by forming a barrier capable of
neutralizing the pathogen before it get to the cells; local and systemic suppression of the
activation of damaging immunological responses (this type of response is termed as oral
tolerance); systemic immune responses including generating serum antibodies such as IgG
and cell-mediated immunity such as by cytotoxic T lymphocytes (CTL) [5].
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Particularly, oral tolerance is defined as the specific suppression of humoral and / or cellular
immune responses, such as antibody formation of different isotypes, production of
inflammatory cytokines, and cellular immune responses including lymphocyte proliferation,
delayed type-hypersensitivity reactions, etc. to an antigen by prior administration of the
same antigen through the oral route [6]. Tolerance should not be restricted to the local
intestinal tissue but also include the systemic immune system [6]. It is an active adaptive
immune response rather than passive unresponsiveness or blindness of the immune system
to exogenous antigens. It is “any mechanism by which a potentially injurious immune
response is prevented, suppressed, or shifted to a non-injurious class of immune responses
[7].”
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Currently, intravenous infusion of recombinant protein is a routine treatment for genetic
deficiencies such as hemophilia and lysosomal storage diseases. However, immune
responses develop in a certain percentage of patients receiving the therapeutic protein, which
represents a big hurdle for therapy [8–10]. All these urgently call for an efficient immune
tolerance protocol. Due to the absence of toxicity, easy administration, and targeting of a
specific antigen, oral tolerance is a very attractive candidate. Indeed, people have
successfully lowered antibody titers and cell mediated immunity with oral tolerance therapy
in animal models of autoimmune diseases and inflammatory diseases, including
experimental autoimmune encephalomyelitis (EAE), uveitis, thyroiditis, myasthenia gravis,
arthritis, diabetes, experimental colitis, as well as graft-versus host disease, allergy, antiphospholipid syndrome, asthma, stroke, and atherosclerosis [11]. Several clinical trials have
also been conducted in multiple sclerosis, uveitis, thyroid disease, Crohn’s disease,
rheumatoid arthritis, hepatitis, and diabetes [7, 12]. The results from human studies have
yielded limited success, possibly due to inappropriate selection of dosage and delivery
methods, indicating there is still a long way to go in understanding the mechanisms of oral
tolerance. The present review will focus on the molecular and cellular mechanisms currently
known to direct oral tolerance, emphasizing clinical applications of oral tolerance in protein
therapy, and discussing several emerging and promising delivery methods for oral tolerance
therapy.

2. Mechanisms
2.1 GALT
The intestine has the most abundant populations of immune cells, with every meter of
human small intestine housing 1012 lymphoid cells [13]. These immune cells are located in
three compartments: scattered throughout the epithelium; in the lamina propria of the
mucosa; or residing in the gut-associated lymphoid tissue (GALT), which are organized
lymphoid aggregates along the submucosa of the entire small intestine [14]. Consisting of
three parts - Peyer’s patches, appendix, and isolated lymphoid follicles, the GALT contains
approximately 5x1010 lymphocytes [4]. Its structure is similar to lymph nodes in that they
Adv Drug Deliv Rev. Author manuscript; available in PMC 2014 June 15.
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both have follicular B cell zones, inter-follicular T cell zones, and antigen-presenting cells
like dendritic cells (DCs) and macrophages [15]. However, the GALT is not encapsulated
and contains no lymphatic vessels, acquiring antigens directly from the intestinal mucosal
surface [15]. GALT and the mesenteric lymph node (MLN), the largest lymph node in the
body, are considered the primary inductive sites of adaptive immune responses, whereas the
lamina propria and epithelium of mucosa have effector and memory functions (Fig. 1). For
example, B cell differentiate into plasma cells and generating antibodies in lamina propria
with helper T cells getting signals from local antigen presenting DC [14]. Intraepithelial
lymphocytes (IELs) regulate innate and adaptive immune responses. About one IEL can be
found per 10 intestinal villous epithelial cells [16]. The majority of IELs are CD8+ T cells
and express α β or γδ T cell receptors, which is required for oral tolerance. Depletion of γδ
IEL impaired oral tolerance induction and maintenance [17].
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The development of the GALT requires stimulation from commensal microbiota and food
antigens. Newborns develop germinal centers, and IgA positive plasmablasts after 1 month
[18]. Germ free mice have underdeveloped lymphoid follicles and low IgA production,
which normalized after 1-month exposure to conventional gut microbiata [19]. Similarly,
mice on a balanced protein free diet showed immature GALT with reduced IgA [20].
Microbiota play a role in tolerance induction, as numbers of regulatory T cells (Treg), one of
the key cell types in tolerance, were lower in germ-free mice than in normal microbiota mice
[21]. Colonization of germ-free mice studies demonstrated that Clostridium species, but not
B. Fragilis, Lactobacillus, segmented filamentous bacteria (SFB), or Bacteroides,
specifically promoted intestinal epithelial cells to produce transforming growth factor-β
(TGF-β), which leads to Treg differentiation and survival [22].
Interestingly, MLN but not GALT was demonstrated to be essential and sufficient for oral
tolerance (Fig. 1). Clostridium can induce Treg accumulation in mice with deficient Peyer’s
patches and lymphoid follicles [22]. Oral tolerance can be induced in the absence of Peyer’s
patches and M cells [23], though oral tolerance can be induced in Peyer’s patches as well
[2]. Functional MLN are essential for oral tolerance induction as lymphotoxin α deficient
mice, which is a model for Peyer’s patches and lymph node deficiency, lost oral tolerance
induction; whereas reconstitution of MLN with anti-lymphotoxin β receptor antibody was
able to restore oral tolerance [24]. This is additionally supported by a study where surgical
ablation of the MLN resulted in decreased oral tolerance [25]. Similarly, surgical removal of
nose-draining lymph nodes abolished nasal tolerance, which can be restored by
transplantation of nosedraining lymph nodes but not peripheral lymph nodes [26].
2.2 APC
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Orally administrated antigens are sampled by different mechanisms and cell types.
Microfold cells (M cells), DCs, and enterocytes were all reported to actively take up
antigens [27]. In addition, some protein antigens can directly cross the epithelial layer and
get into circulation. The route and mechanism of antigen uptake may be dependent on the
natural characteristics of that antigen [28]. Peyer’s patches might be involved more with
bacteria antigens [29], whereas some haptens might reach the liver via portal vein, which is
believed to play a prominent role in oral tolerance induction [30]. Antigen presenting cells
(APC) in the gut are particularly prone to induce antigen-specific Treg, which migrate and
suppress damaging immune responses and secret antigen non specific cytokines such as
TGF-β, contributing to bystander suppression (Fig. 1) [27].
2.2.1 M cells—M cells, with broad microfolds instead of microvilli on their apical surface,
are mainly located in the follicle associated epithelium that lines Peyer’s patches and
isolated lymphoid follicles in the small intestine (Table 1). M cells take up antigens in gut
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lumen by endocytosis and effectively transport them to professional antigen presenting cells
residing in the subepithelial dome region of the follicles. Antigen loaded APCs further
present the antigens to naïve T cells in the GALT or migrate to gut-draining MLNs [29].
Targeting M cells using a recombinant reovirus protein sigma 1(pσ1) conjugated with
ovalbumin (OVA), enhanced oral tolerance as antibody titers and CD4+ T cell responses
against OVA were greatly suppressed compared with controls. CD4+CD25+ forkhead box
protein 3 (Foxp3+) T cells from the spleen, MLNs, and Peyer’s patches showed dramatically
increased expression of TGF-β and IL-10 (Fig. 1) [31]. In one example, fed antigen
predominantly localized to the interphase between M cells and CD11c+ DC in Peyer’s
patches, consistent with the model that M cells take up antigen and deliver to DC by
transcytosis. Two to five hours after oral gavage, antigen can be found in the liver and
plasma (Fig. 2) [32]. This transcellular-M pathway was also identified as one of the
mechanisms in nanoparticle oral delivery system by fluorescent image studies [33]. Particles
with a diameter of less than 5 µm were able to be taken up by M cells, with a diameter
around 100nm having higher efficiency compared with bigger nanoparticle sizes [34, 35].

NIH-PA Author Manuscript

2.2.2 DC—Intestinal DCs, the major APCs in the gut, are located in the lamina propria,
Peyer’s patches, and MLN [36]. DCs constitutively engulf apoptotic enterocytes, which
sampled intestine luminal antigens. Additionally, DCs under the epithelial of lamina propria
are able to open the tight junctions between adjacent epithelial cells and extend their
dendrites to reach luminal content to acquire antigen directly from intestine lumen (Fig. 1)
[37, 38].
It was suggested that resident DCs in the gut have an intrinsic non-inflammatory
characteristics (Table 1). Compared to splenic DCs, DCs from Peyer’s patches induced
tolerance rather than primed T cells to an effector phenotype [39]. DCs isolated from MLN
and Peyer’s patches induced B cells production of IgA, and T cells expression of guthoming receptors CCR9 and α4β7 [40, 41], which are critically required for oral tolerance
[11]. In vivo expansion of DCs using flt3 ligand enhanced oral tolerance [36]. Although
intestinal antigens were shown to reach the circulation and peripheral lymph nodes [42],
evidence indicated that it is not sufficient to induce significant responses and oral tolerance
relies on the gut DCs uptake of antigens and subsequent migration to MLN on a CCR7dependent manner [25].
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Besides inducing Treg, gut’s DCs are able to initiate effector T cells in response to invasive
pathogens, depending on subsets of DCs involved and surface receptors engaged [43].
Plasmacytoid or conventional CD11c+ DCs, CD103+ DCs, and CD11b+ DCs may be
specialized for inducing oral tolerance. In an asthma model, transferring splenic CD11c+
plasmacytoid DCs (pDCs) isolated from OVA-fed mice transferred tolerance [44]. In a
delayed type hypersensitivity model, in vivo depletion of pDCs diminished oral tolerance
[45]. Adoptively transferring pDCs from liver and MLN but not spleen of antigen fed
animals transferred tolerance. A study showed pDCs that contributed to around 70–80%
anergy/deletion of antigen-specific cells [45]. In a contact dermatitis model, pDCs first
abrogated a large fraction of antigen-specific CD8+ T cells in liver and MLNs, followed by
induction of suppressive Treg [30]. CD103+ DCs produced retinoic acid, which is important
in boosting Foxp3 Treg [46]. CD103+ DCs also expressed indoleamine-2,3-dioxygenase
(IDO), required for the induction of Foxp3 Treg and development of oral tolerance. TGF-β,
as well as prostaglandin E2, was involved in inducing IDO expression in CD103+ DCs [47].
CD11b+ DCs, which produced IL-10 and IL-27, increased dramatically during oral
tolerance. IL-27 enhanced IL-10 production by Treg [48]. CD11b deficient animals were
unable to induce oral tolerance [49].
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Gut mucosal environment is important in educating DCs (Fig. 1). As they migrate from the
lamina propria to the MLNs, DCs are influenced by local factors and crosstalking with
different cell types. Intestinal epithelial cells are in close contact with lamina propria DCs
and have been shown to condition DCs into “tolerogenic cells” by releasing TGF-β, retinoic
acid, and thymic stromal lymphopoietin [50, 51]. Other innate cells may play roles, such as
lamina propria macrophages producing large amount of IL-10 and inhibit DCs induction of
TH-17 cells [52]. MLN stromal cells are essential for DC induced CCR9 expression of T
cells and express high level of retinoic acid-producing enzymes [53]. Orally immunized
memory CD4+ T cells secrete IL-4 and IL-10 to educate DCs, which further induce naïve T
cells to produce the same cytokines as the immunized T cells producing [54].
2.3 T cell responses
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T cell responses play a central role in immunity. Oral tolerance is orchestrated by distinct
mechanisms (Fig. 3). Generally, when given a high dose oral antigen, it induces T cell
deletion/anergy with IgA production; when adding certain adjuvants, the response can be
converted to systemic activation such as CTLs and IgG. When given low doses, it results in
active suppression with IgA secretion and induction of Treg producing IL-4, IL-10 and
TGF-β [6]. These two mechanisms may occur simultaneously and overlap instead of being
mutually exclusive, as they shared some of the same characteristics such as similar
cytokines production and anergic T cells perform regulatory function identical to Treg [55],
which will be discussed further below. Suppression of specific effector T cell responses by
oral antigen administration has a different susceptibility. For example, Th1 type
inflammation can be easily suppressed long-term with lower doses of antigen [56]. Th2
responses need higher amounts of antigen or increased feeding frequency [57], except for
IL-4 dependent IgE response, which is highly susceptible to oral tolerance induction [58].
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The concept of suppression mediated by T cells was first described in the 1970’s [59]. More
than 1000 scientific papers were published on that topic, mainly referring to CD8+ (Lyt- 2)
T cells [59, 60]. However, due to lack of specific markers and poor characterization,
suppressor T cells were nearly abandoned by the end of 1980’s [61]. In the mid-1990s, a
new subset of suppressive CD4+ T cells was characterized as regulatory T cells (or “Treg”).
Besides high level of IL-2 receptor (IL-2Rα or CD25) expression, other markers were also
reported such as transcriptional factor Foxp3, cytotoxic T lymphocyte antigen 4 (CTLA-4),
and glucocorticoid-induced tumor necrosis factor receptor family-related gene (GITR) [59].
Commonly, CD4+ T cells now are divided into two distinct lineages, conventional T helper
(Th) cells and Treg [59]. Conventional Th cells regulate the adaptive immunity by activating
other effector cells including CD8+ CTLs, B cells, and macrophages in an antigen dependent
manner. Treg are defined as T cells diminishing potentially harmful activity of Th cells [62].
Treg exhibit regulatory functions to suppress an effector T cell response including inhibition
of T cell proliferation and blockade of inflammatory cytokines release. Treg can transfer
tolerance to naïve recipients [59]. They either secret high levels of IL-10 and TGF-β, or
require TGF-β for the development [62].
It is well accepted that oral antigen administration activates or induces Treg, though the
mechanisms are not completely clear, most likely involves cross talking between
macrophages, DCs and T cells (Fig. 3). As mentioned above, gut DCs had the intrinsic
characteristic to induce tolerogenic T cells response rather than prime effector T cells. An
interesting link between apoptosis and generation of Treg has been described in high dose
feeding. Feeding high doses antigen in mice seems to increase the susceptibility of
lymphocytes to apoptosis [63]. Similarly, human lamina propria T cells show increased
susceptibility to Fas-mediated apoptosis upon CD2 pathway stimulation [64]. Macrophages,
which clean up the apoptotic cells through αvβ3 integrin, exhibit up-regulation of TGF-β
and down-regulation of pro-inflammatory cytokines production [65]. In addition, a subset of
Adv Drug Deliv Rev. Author manuscript; available in PMC 2014 June 15.
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gut DCs were discovered to take up apoptotic enterocytes, and have relatively low
stimulatory activity for T cells [66]. Apoptotic T cells also secrete TGF-β, as a result from
existing cytokine redistribution following loss of mitochondrial membrane potential [67].
TGF-β increased from macrophages, DCs and apoptotic T cells, is a critical cytokine in the
differentiation and survival of Treg. Another explanation for high dose oral tolerance is
anergy of specific T cells. Anergy is the basis of peripheral tolerance to self-antigens. It also
plays role in oral tolerance, first indicated that T cell tolerance can be reversed by exogenous
IL-2 in vitro [68]. Anergic T cells are not just passive in the tolerance they evoke. They
produce cytokines including IL-4, IL-10, TGF-β and act as suppressor cells in vivo and in
vitro [69, 70]. Anergic CD4+ T cells from mice tolerized by feeding casein can mediate
active suppression when transferred to severe combined immunodeficiency (SCID) mice
[71].
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Various subsets of Treg in oral tolerance have been reported, such as thymus derived Treg
or natural Treg, induced FoxP3+ Treg, Tr1 cells, and Th3 cells (Table 1). Thymus derived
CD4+CD25+Foxp3+ Treg or natural Treg play critical role in abrogation of auto-immunity
and maintain self-tolerance [72]. In addition, they involve in suppressing immune responses
toward commensal bacteria in the gut [73]. They are reported to be unregulated in oral/
mucosal tolerance [11]. However, in a mice model containing a monoclonal population of
CD4+ T cells specific for OVA crossed on a RAG-1 deficient background, it was
demonstrated that oral tolerance to OVA was effectively induced without thymus-derived
Treg [74].
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Peripherally induced or adaptive Treg are essential for oral tolerance [75]. They develop
outside the thymus within specific microenvironment. For example, CD4+CD25+Foxp3+
Treg were markedly induced in Peyer’s patches of OVA TCR transgenic mice fed high
doses of OVA. They have suppressive properties in vitro and mediate tolerance transfer to
naive animals [76]. CD4+CD25+CTLA4+ Treg were upregualted as long as 4 weeks after
OVA feeding. They expressed high level of TGF-β and IL-10 and mediate adoptive
tolerance transfer in BALB/c mice [77]. In a high dose OVA feeding model, induced
CD4+CD25+ Treg expressed TGF-β and were anergic T cells. Their oral tolerance was
IL-18 dependent [78]. One subset of CD4+ T cells producing TGF-β is termed Th3 cells,
which was initially isolated and cloned from the lymphoid tissues of mice tolerated by low
dose antigen feeding (Table 1) [79]. They appear to be dependent on IL-4 rather than IL-2
for growth and may produce variable amounts of Th2 cytokines like IL-4 and IL-10 [6].
Another subset of IL-10 producing type 1 regulatory T cells, named Tr1 cells, mediate
suppression through IL-10 and induce Foxp3+ Treg, are reported to be involved in lose dose
oral tolerance (Table 1) [74, 80]. A membrane-bound form of TGF-β containing latencyassociated peptide (LAP) has been identified [81]. LAP+ Treg occurs in both CD25+ or
CD25− cells (Table 1) [82]. All these subsets are not mutually exclusive as they produce
similar cytokines. For instance, Foxp3+ Treg, Th3 cells, and Tr1 cells, all secrete IL-10. As a
result of different experimental settings and lack of exclusive markers, one can hardly
determine what percentage a certain cell type contribute in oral tolerance. Moreover, various
subsets might act in synergy and connected to each other in performing their functions. As
such, Th3 and Tr1 cells induce Foxp3+ Treg through TGF-β and IL-10 [83].
Additionally, a subpopulation of CD8+ lymphocytes might be also involved in tolerance
induction. Intestinal epithelial cells (IEC) activated CD8+ T cells with a regulatory function
[84]. Feeding a MHC class I immunodominant peptide of OVA induced CD8+ T cells with
regulatory function. These cells inhibited Th1/Th17 responses but not Th2 responses [85].
Defects in CD8+ T cells were observed in inflammatory bowel disease patients and
correlated with a failure to induce oral tolerance in these patients [86]. However, anti-CD8
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2.4 Cytokines
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2.4.1 Transforming growth factor-β (TGF-β)—TGF-β a multifunctional polypeptide
involved in various cellular processes, such as extracellular matrix production, angiogenesis,
differentiation, proliferation, apoptosis, and immunomodulation [89]. Three isoforms exist
in mammals including TGF- β1, TGF-β2, and TGF-β3. TGF-β1 is the foremost in leukocyte
populations [89]. TGF-β has emerged as a key regulator of both innate and adaptive immune
responses, in a context dependent manner [89]. Abundant in the gut microenvironment,
TGF- β is pivotal in epithelial cell differentiation, IgA class switching, and has strong
immunosuppressive effects on lymphocytes [90]. TGF-β mediates immune tolerance via
induction and maintenance of Foxp3+ Treg. In vitro studies revealed that TGF-β activates
naïve T cells into Foxp3+ expressing T cells with suppressive capacity [91]. Neutralization
of TGF-β during induction of oral tolerance diminished Foxp3 expression in MLN and
spleen [74]. TGF-β inhibits T cell proliferation with no exogenous IL-2, and decreases the
differentiation of naïve T cells into effector Th1 and Th2 cells via the downregulation of Tbet and GATA3 [92–94]. TGF-β is secreted as an inactivated form. Latent TGF-β can be
activated by gut DCs and IECs through integrins αvβ8 and α4β6 [95, 96]. Mucosal DCs
expressed more αvβ8 than splenic DCs and release more bioactive TGF-β, which might in
part explain why mucosal DC inducing more Foxp3+ Treg [95].
Involvement of TGF-β in oral tolerance was extensively documented (Fig. 4). TGF-β
production was unregulated in Peyer’s patches, lamina propria and draining lymphoid
tissures after induction of oral tolerance [97, 98]. TGF- β producing Th3, other CD4+ cells,
and CD8+ T cells were isolated and cloned from the Peyer’s path and MLN of orally
tolerized mice, and peripheral blood of humans fed MBP [6, 99]. In the experimental models
of EAE and IBD, oral antigen feeding reduced diseases dependent on TGF-β productions, as
neutralized TGF-β with antibodies impaired the development of oral tolerance [100, 101].
TGF-β deficient mice die soon after birth from wide spread inflammation [102]. Using an
anti-LFA-1 antibody to inhibit inflammation in TGF-β deficient mice, it was shown that low
doses and high dose feeding of OVA lymphocytes had reduced proliferation [103].
However, some mice in low dose feeding exhibited no tolerance or even priming systemic
proliferation responses; and the degree of tolerance was only partial for all systemic
responses compared with wild type mice [103]. Thus, TGF-β plays a critical role in oral
tolerance, although it may not be the exclusive mechanism involved.
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The source of TGF-β in gut is not only from CD4+ or CD8+ T cells. Many other cell types
such as macrophages and enterocytes can also produce this cytokine [104]. One study even
indicated that antigen-pulsed epithelial cells might inhibit T cell activation through secretion
of TGF-β [105].
In addition to the secreted form of TGF-β, an active membrane-bound form was also
described. Latency-associated peptide (LAP) is the amino-terminal domain of the TGF- β
precursor peptide. After cleavage, LAP forms the latent complex with TGF- β via
noncovalent association [82]. Certain Treg express LAP and TGF- β on their cell surface,
which is associated with the suppressive activity of Treg [81, 82]. LAP+ Treg are expanded
in oral tolerance, both CD4+CD25+ and CD4+CD25- [82]. Anti-TGF- β antibody can
reverse the suppressive effects of LAP+ Treg [83].l
2.4.2 Interleukin-10 (IL-10)—IL-10 initially has been described as a Th2 type cytokine to
suppress Th1 type responses, including cytokines IL-2 and IFN-γ production and cell
proliferation in oral tolerance, which is still widely used in measurement of oral tolerance
Adv Drug Deliv Rev. Author manuscript; available in PMC 2014 June 15.
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induction by many researchers [54, 106]. Low dose antigen feeding induced IL-10 and IL-4
in tolerated mice [107]. However, oral tolerance also inhibits Th2 type responses although
the susceptibility is different [57]. The role of Th2 cells in mediating oral tolerance is further
questioned since neutralizing IL-4 with antibody or IL-4 deficient mice, which is a model
for Th2 cell deficiency, still develop oral tolerance [108].
IL-10 is now regarded as a broad anti-inflammatory cytokine (Fig. 5). It not only inhibits
Th1 responses, but also down-regulate MHC class II and costimulatory molecules
expression [109]. Besides Th2 cells, IL-10 can be secreted from a variety of cells.
Specifically, one regulatory subset of CD4+ T cells mainly producing IL-10, are named Tr1
cells [110]. Other populations of CD4+ T cells are capable of secreting IL-10, such as Th3
cells, Th17 cells, Foxp3+ Treg [109]. Epithelial cells, macrophages, NK cells, B cells, DCs
and CD8+ T cells, all have been reported to produce IL-10 [109]. An interesting linking has
been revealed between IL-10 producing mucosal APC and IL-10 producing T cells, as
plasmacytoid DCs from MLN, CD11b+ DCs from PP, and CD11b+F4/80+ lamina propria
macrophages can induce IL-10 producing T cells through their own secretion of IL-10 [52].

NIH-PA Author Manuscript

Highly expressed in the intestine, IL-10 is critical in establishing tolerance to intestinal
commensal bacteria. IL-10 deficient mice develop spontaneous colitis associated with
abnormal T cell activation [111]. Exogenous IL-10 was able to restore tolerance in the
colitis mice [109]. It has been reported that all IL-10 producing T cells in the colonic lamina
propria express Foxp3, but not in the small intestine [112]. Selective deletion of IL-10 in
Foxp3+ T cells in the colon lead to spontaneous colitis, indicating IL-10 is important in
Foxp3+ Treg suppressive function in the colon [113]. In addition, IL-10 producing
macrophages in lamina propria are crucial in supporting the Foxp3+ Treg function as well
[114].
The role of IL-10 in oral tolerance is controversial. Lots of IL-10 producing T cells exist in
the gut microenvironment [115]. Antigen feeding increases IL-10 production even more,
especially in PP, MLN, also in spleen and serum [80]. Tr1 cells are induced in oral tolerance
[116]. However, oral tolerance can still be induced in mice treated with anti-IL-10
antibodies and anti-IL-10 antibodies do not abrogate established tolerance in vivo [117]. But
in one study with IL-10 deficient mice treated recombinant IL-2, multiple feeding of antigen
failed to induce tolerance [80]. Another IL-4 and IL-10 knockout mouse study demonstrated
that both cytokines are required for low dose oral tolerance [118].
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Cytokines are essential for oral tolerance induction. Cross-talking between different
cytokine producing cells occurs in oral tolerance. TGF- β may induce the differentiation of
IL-10 producing cells [112, 119]. IL-10 may be involved in TGF-β production as anti-IL-10
treatment decreased TGF-β levels [120].
Besides the two major suppressive cytokines TGF-β and IL-10, other cytokines may also be
involved. IFN-γ regulates the expression level of adhesion molecules essential for Treg
migration [121]. It is reported that oral tolerance cannot be induced in IFN-γ deficient mice
or adoptive transfer of TCR transgenic T cells with an IFN-γ deficient background [121,
122]. However, other reports described that deficiency of IFN-γ does not affect oral
tolerance induction or maintenance [123, 124]. Some anti-tolerance cytokines have also
been described. IL-6 and IL-17 treatment can decrease the Treg cell population and impair
tolerance [125]. Oral tolerance suppresses Th17 cells, which secrete high amounts of IL-17
and IL-22 [49].
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Many signal pathways are important in regulating immune responses for oral tolerance
(Table 1). Cyclooxyenase-2 (COX-2) is the inducible enzyme in arachidonic acid
metabolism. PGE2, the product of COX-2 was shown to directly induce Foxp3 expression in
T cells [126, 127]. Selective COX-2 inhibition led to loss of tolerance to oral antigen
administration [126]. NF-κB and MAPK pathways are essential for Treg development and
Akt has a negative effect on Treg [128]. Retinoic acid and Foxp3 are two pathways which
were intensively studied, and will be discussed further below.
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2.5.1 Retinoic acid (RA)—Retinoic acid (RA) is the metabolite of vitamin A by alcohol
dehydrogenase (ADH) and retinal dehydrogenase (RALDH) [129]. It is critical for proper
function of mucosal DCs in oral tolerance. Mucosal DCs induction of gut homing receptors
including αEβ7 and CCR9 in T and B cells is dependent on the ability of DCs to convert
vitamin A into RA [130, 131]. RA regulates Th17 cell responses, contingent on the local
cytokine environment [132, 133]. TGF-β mediated Foxp3+ Treg induction can be boosted
by RA [134, 135]. It is well known that mucosal DCs have a greater capacity to induce
Foxp3 expression in T cells than non-mucosal DCs, which is associated with the DCs ability
to convert vitamin A into RA [134]. CD103+ DCs in MLN express high level of Aldhla2,
the gene encoding RALDH2 [46]. So that CD103+ DCs but not CD103− DCs can induce
Foxp3+ Treg in the absence of exogenous RA and TGF-β. CD103− DCs have weaker
induction of Foxp3+ Treg compared with CD103+ DCs even in the present of exogenous
TGF-β [46].
Multiple pathways might mediate the mechanisms of RA enhancement of Foxp3+ Treg
induction by TGF-β. First, RA inhibits the production of some cytokines in effector and
memory T cells, which suppress naïve T cell differentiation into Foxp3+ Treg [136, 137].
Furthermore, RA suppresses the effects of pro-inflammatory cytokines on naïve T cells,
such as down-regulation of IL-6 receptors levels [138]. Vitamin A deficiency results in
increased inflammation [129]. In addition, RA increases TGF-β signaling by raising the
expression of Smad3 [138]. RA up-regulates Foxp3 expression directly via binding to the
promoter region with RA receptor α [139]. Moreover, RA attenuates the co-stimulation
from interfering Foxp3+ Treg differentiation [135]. However, there is a report that RA’s
effects can be independent of inhibitory cytokines and RA induction of Foxp3 expression is
largely Smad3 independent [140]. Thus, the effects of RA are most likely integrative instead
of just relying on a single pathway.
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Besides mucosal DCs, other cell types in the gut are able to convert vitamin A into RA, such
as intestinal epithelial cells, MLN stromal cells, and lamina propria macrophages [51–53].
The epithelial cells and stromal cells generated RA might be transferred to DC as a
mechanism of local education of DCs. DCs were reported to take RA from outside, store it,
and acquire tolerogenic characteristics [141]. Macrophages might function similar way with
DCs in that macrophages induce Foxp3+ Treg dependent on RA and TGF-β [52]. The
difference is macrophage require IL-10 in inducing Treg besides RA and TGF-β [52].
2.5.2 Treg expressing transcription factor FoxP3—Foxp3 belongs to the forkhead /
winged-helix family of transcriptional factors and is highly conserved in humans [142, 143].
Acting as the activator or suppressor, Foxp3 binds to the promoter region of 700–1100
genes, most of the genes associated with TCR signaling [142, 143]. The expression of Foxp3
is largely in T cells, mainly in CD4+ T cells, some CD8+ T cells also express it, very low or
undetectable in B cells, natural killer cells, macrophages and DCs [142, 143]. To date,
Foxp3 is considered one of the most reliable Treg markers, although some reports found
Foxp3 also exist in non-Treg [144]. There is an overlap of expression between Foxp3 and
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CD25, the traditional Treg marker. In lymph nodes and spleen, most CD4+CD25+ cells
express Foxp3 [144, 145]. Although Foxp3 can be positive in CD4+CD25+ and CD4+CD25−
cells, it is more abundant in CD4+CD25+ cells in mice [145].
Foxp3 is a pivotal factor for Treg function. Foxp3 mutations cause X-linked autoimmunity
allergic dysregulation syndrome and immunodysregulation, polyendocrinopathy,
enteropathy, X-linked syndrome, which are severe autoimmune diseases in humans [146–
148]. Scurfy mice, the mice orthologue of Foxp3 deficiency, develop lymphoproliferative
disorder and die one month after birth [149]. T cell targeted deficiency of Foxp3 lead to
lymphoproliferative disease [144]. Retroviral-mediated Foxp3 expression in naïve T cells
resulted in those T cells acquiring Treg-like phenotype and functions [150, 151]. Foxp3
transgenic mice show markedly increased number of CD4+CD25+ Treg, and CD8+ T cells
expressing Foxp3 also demonstrate immunosuppressive activity [152]. Continuous Foxp3
expression is associated with maintenance of the Treg in the periphery [153]. Expression of
Foxp3 is stabilized by demethylation, and this epigenetic modification is essential for the
development of a permanent Treg cell lineage [154].

NIH-PA Author Manuscript

Foxp3+ Treg can convert to conventional T cells. In vitro TGF- β induced Treg with partial
promoter demethylation lost Foxp3 expression and suppressive activity upon restimulation
in the absence of TGF-β [154]. A large fraction of labeled Foxp3+ Treg became Foxp3−
after 4 weeks transfer into T cell deficient mice. Some of them converted to Th1 cells, Th2
cells, and Th17 cells in lymph nodes and spleen [155, 156]. Some converted to Tfh cells that
function in assisting IgA production by B cells in Peyer’s patches [157]. The mechanism of
this conversion is not clear, possibly involving inflammatory cytokines. IL-6 can decrease
Foxp3 expression and reprogram Treg into Th17 cells [158]. In the presence of
inflammatory signals, Treg differentiated into Th17 cells in vivo [159].
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Glucocorticoid-Induced Tumor necrosis factor Receptor family-related protein (GITR; also
called TNFRSF18 or CD357) is constitutively expressed on Treg cells and is inducible upon
activation on naïve CD4+ T cells [160–162]. Although the number of FoxP3+ Treg is normal
under steady state, it is significantly induced in wild-type mice after administration of
soluble Fc-GITR-L fusion protein, which has been shown to transiently induced tolerance to
the coagulation factor IX expression in a murine model of hemophilia B [163]. Transgenic
hCD19-GITR-L mice also showed increased numbers of FoxP3+ Treg and were more
resistant to the induction of experimental autoimmune encephalitis (EAE) [164]. In addition
to regulating the balance between Teff and Treg cells, the GITR-L / GITR interaction also
controls the development of DC, macrophages and/or monocytes. Therefore, the numbers of
tolerogenic CD103+ DCs and pDCs are reduced in GITR deficient mice, thereby causing the
expansion of Th1 cells and inhibiting the development of FoxP3+ Treg after their exposure
to the large amount of food antigens as well as to commensal bacteria [165]. GITR-L / GITR
engagement may also potentially influence the establishment of oral tolerance by a reverse
signaling through GITR-L in pDC. For example, GITR-L engagement by GITR::Fc fusion
protein induced expression of IDO in pDC, a pathway that may also aid in inducing oral
tolerance [166].

3. Therapeutic proteins & disease targets
Hemophilia A and B are X-linked bleeding diseases with a deficiency of coagulation factor
VIII (F.VIII) or factor IX (F.IX), respectively. Current clinical treatment is based on
periodical intravenous administration of the deficient coagulation factor. The most
problematic complication associated with therapeutic protein replacement is the
development of neutralizing antibodies (inhibitors) that occurs in treatment of 25–30% of
hemophilia A and of 2–4% of hemophilia B patients. Some hemophilia B patients with
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inhibitors are also at risk for severe allergic / anaphylactic reactions to F.IX, contributing to
a higher morbidity and mortality rate. Inhibitors develop due to the induction of adaptive
immune responses against the therapeutic proteins, which are perceived as non-self antigens.
High-level inhibitors decrease the therapeutic effects of coagulation factors and require
either bypass therapy or immune tolerance induction (ITI). However, several disadvantages
limited these applications: high cost; inability to induce tolerance in some patients; and
requirement for frequent monitoring [167, 168].
Pompe disease, which is an autosomal recessive lysosomal storage disorder with a
deficiency of acid α-glucosidase (GAA), causes death early in childhood due to
hypertrophic cardiomyopathy and respiratory failure. Similarly, enzyme replacement
therapy (ERT) based on intravenous infusion of recombinant human GAA, is the standard
therapy, which prolongs the life of affected infants. However, anti-GAA antibodies
responses develop and compromise the beneficial effects. Only recently, immune tolerance
protocols to prevent anti-GAA antibody formation in patients with infantile onset disease are
being developed to maintain the efficacy of ERT [10]. However, these heavily rely on
immune suppression. One study addressed oral tolerance as an alternative (Table 2). Oral
recombinant human GAA administration successfully lowed anti-GAA antibody titers in
C57BL/6 and Balb/c mice. GAA specific IgE titers in post-immune serum were lowered too
[169].
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Oral tolerance for inherited protein deficiencies offers many advantages in suppressing
adaptive immune responses: low costs; low adverse effects; easy delivery; and higher
efficacy in achieving antigen specific peripheral tolerance. Several studies have been
performed in hemophilia (Table 2). F.VIII orally administrated with sodium bicarbonate at a
dose of 1250 IU once daily for 3 months successfully decreased F.VIII inhibitors titers in
two of three patients, lasted for 6 months after termination of the treatment. The other
patient showed no decrease of inhibitors but still had a decreased in vivo proliferation rate of
mononucleated cells and reduced cytokine production, including IL-6, IL-1β and TNFα[170]. Another study reported that orally administered F.VIII at intervals ranging from 1
day to 1 week, dosage increasing form 20 to 70 units/kg, markedly diminished the inhibitors
from 42 BU/ml to 11 BU/ml in one patient. However, the inhibitors relapsed when high
dosage of prothrombin complex concentrates (contains F.VIII light chain fragment) were
administrated due to bleeding control [171]. Mouse studies showed that F.VIII-C2 oral and
nasal applications significantly suppressed antibody and inhibitor formation to this domain
but not to the entire F.VIII protein. Tolerance was associated with increased IL-10
production and could be adoptively transferred. However, tolerance was not sustained after
additional F.VIII-C2 injections [172]. Oral delivery of human F.IX bioencapsulated in
chloroplast transgenic plant cells was successful in controlling inhibitor formation to factor
replacement therapy in hemophilia B mice with F9 gene deletion long-term [32]. Moreover,
this treatment also prevented IgE formation and the associated life-threatening anaphylactic
reactions that normally occur in response to repeated intravenous administration of human
F.IX in these mice (Fig. 2).
In contrast to the still limited data in genetic disorders caused by single gene deficiencies,
oral tolerance has initially and most intensively been studied in autoimmune disease. These
investigations include well-established animal models and clinical trial trials, particularly in
multiple sclerosis (MS), rheumatoid arthritis (RA), and diabetes (Table 2). For example, oral
insulin has been used to slow or prevent diabetes in the non-obese diabetic (NOD) and in a
viral induced diabetic mouse models, accompanied by decreased IFN-γ and increased IL-4,
IL- 10 and TGF-β responses to the insulin antigen. In other work, oral antigens tolerized
mice showed markedly reduced disease severity in collagen-induced arthritis model,
adjuvant arthritis model, pristine-induced arthritis model, and silicone-induced arthritis [11,
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12]. Studies from different groups demonstrated that oral myelin basic protein (MBP)
significantly suppressed experimental autoimmune encephalitis (EAE), which is a murine
model for MS [6]. Human trials have also been performed in autoimmune diseases, MS, RA,
and diabetes[11, 12]. Although clinical efficacy has been limited, and approval of an oral
tolerance drug is still a distance away from reality, these trials continue to yield valuable
information. For example, no systemic toxicity and exacerbation of diseases have been
observed. Several small studies showed positive effects but also indicate a need for further
optimization of dosage, scheduling of the regimen, and delivery methodologies [11, 12].

4. Delivery methods
The majority of the animal experiments and human trials were conducted using protein
concentrates or solutions. Although the suppressions of immune responses from animal
studies were dramatic and sufficient to protect from diseases, clinical trials in patients were
generally of limited success. One possible explanation is that the doses of antigens applied
to humans were low compared with that of mice, due to the large absorptive intestinal
mucosal area [7, 173]. Thus one critical question to address in oral tolerance clinical
applications is to enhance the efficacy or to obtain sufficient amounts of antigen for repeated
oral administration.
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Transgenic plants are an attractive system for the production of oral antigens. Plants are easy
to produce for large scale-up at low cost with no need of expensive culture media. They are
highly amenable to oral application without extensive protein purification. They are stable
and easy to store. The protein and peptide synthesized in plants can be structurally and
functionally identical to their native counterparts, and are protected by bioencapsulation.
Indeed, many publications have reported the production of pharmaceutical proteins such as
antibodies, cytokines, enzymes, vaccine antigens, hormones etc in plant cells. Some of them
have entered clinical development stage. Transgenic plants including tobacco, rice, potato,
lettuce, and tomato have all been created, either as a stable transgenic like nuclear system or
transient expression using plant virus vectors [174]. Several interesting studies have tried
plant material in oral tolerance therapy in animal models of allergies, rheumatoid arthritis,
diabetes and hemophilia B. One study, using transgenic rice with mite allergen encapsulated
in endoplasmic reticulum derived protein bodies in mice, markedly suppressed allergenspecific IgE and IgG production, allergen-induced CD4+ T cell proliferation and production
of Th2 cytokines, infiltration of eosinophils, neutrophils, and mononuclear cells into the
airways [175]. Another group generated transgenic rice with T cell epitopes of cedar pollen
fused with cholera toxin B (CTB), suppressed allergen specific IgE responses and pollen
induced clinical asthma symptoms [176]. Oral application of CTB-fused proinsulin fusion
protein expressed in lettuce and tobacoo chloroplasts, significantly inhibited insulitis in
NOD mice. Insulin producing β cells were greatly preserved; blood and urine glucose levels
were reduced; and IL-4 and IL-10 were increased [173]. Feeding DBA/1 mice, which is a
model of rheumatoid arthritis, with transgenic rice seeds of collagen type II peptides,
lowered serum specific IgG2a responses against subsequent and repeated intraperitoneal
injection of type II collagen [177]. Our studies utilized oral delivery of chloroplast
transgenic (“transplastomic)” leaf material containing CTB-fused F.IX to control inhibitor
formation and anaphylaxis to human F.IX in hemophilia B mice in a highly effective manner
for at least 7 months, about 40% of the life span for the mouse strain used [32]. From these
early plant studies, it appears that the effective dosage required for plant delivery system is
considerably lower than for conventional protein or peptides concentrates, especially when
the plant expressed protein or peptide were fused with a mucosal carrier like CTB. For
example, 1 mg of porcine insulin twice a week for 5 weeks, and then weekly for 1 year was
used to effectively suppress diabetes in NOD mice [178]; whereas only about 14 µg of the
CTB-proinsulin fusion protein expressed in tobacco once a week for 7 weeks markedly
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suppressed insulitis in NOD mice [173]. In the hemophilia A mouse studies, 500 µg of
F.VIII C2 peptide protein concentrations was used for oral administration to induce partial
immune tolerance in hemophilia A mice model; whereas we used only 0.14 µg to 2 µg F.IX
with CTB fusion expressed in tobacco induced complete oral tolerance in the hemophilia B
mouse model [32, 172]. 100 µg collagen type II (250–270) synthetic peptide every other day
for 20 days (total 1 mg) vs 25 µg same peptide expressed in rice seeds per day for 2 weeks
(total 350 µg) successfully suppressed immune responses against type II collagen in DBA/1
mice [177, 179].
CTB, the nontoxic cholera toxin B subunit, is a potent antigen-adjuvant. It binds to GM1
ganglioside expressed on the live intestinal epithelial cells, and facilitates uptake via an
actinand ATP-dependent processes [173, 180]. The binding of CTB does not alter the
organization of the plasma membrane and has minimal effect on the diffusion of other
molecules [180]. CTB-coupled antigens have been shown to suppress DC activation and
promote induction of FoxP3+ Treg [181–183].
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One of the reasons for requirement of lower dosage of protein bioencapsulated in plant cells
is protection of antigens from degradation in the stomach by acids and enzymes [184]. Also,
transplastomic plants are capable of very high levels of expression of therapeutic proteins,
up to 70% of the total leaf protein [185]. In addition, multi-gene engineering to express
several antigens in a single transformation event is a major advantage [185–187]. Plant cells
can be lyophilized and stored at room temperature for several months or years without
degradation of antigens or autoantigens [188]. Most importantly, harvest of leaves before
emergence of reproductive structures and maternal inheritance of transformed chloroplast
genomes containing genes coding for therapeutic proteins offer several layers of biological
containment of transgenes [189]; such containment addresses one of the major
environmental concerns in using genetically modified plants. Therefore, plant delivery
system has several unique advantages in delivering autoantigens to confer oral tolerance.
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Nanometer-sized particles like proteins and viruses are actively involved in diverse cellular
activities. Recently, synthetic nanoparticles were developed to transport drugs and proteins
of interest into target cells. Oral formulation of nanoparticles encapsulates drugs or proteins,
protects and releases them in a temporally or spatially controlled manner. Particle size,
surface charge, and surface chemistry all influence delivery efficacy. The particle surface
can be modified or coated to enhancing specific targeting. For example, coating insulinnanoparticles with pH sensitive material or conjugating with vitamin B-12 or derivatives can
greatly enhance insulin absorption and bioavailability. To date, the well recognized oral
nanoparticle formulation is complex, multilayered, mucoadhesive, biodegradable,
biocompatible, and acid-protected [190]. A few oral tolerance studies have used nanoparticle
as a delivery method. Polylactic-co-glycolic acid (PLGA) nanopartilces delivered collagen
type II protected experimental arthritis in mice [191]. Another study used poly-ethylene
glycol (PEP) conjugated collagen peptides suppressed collagen-induced arthritis [192].
Besides protein, peptide or drugs, cDNA can be effectively delivered using chitosan, which
is a cationic polymer interacts with cDNA via electorstatic interactions, protects entrapped
cDNA from digestion and facilitates gut delivery. Using chitosan-based nanoparticles,
F.VIII DNA was successfully delivered into hemophilia A knockout mice with functional
F.VIII protein detected in plasma at a peak level of 2–4% F.VIII activity. 13 out of 30 mice
showed a phenotypic correction in bleeding challenge [193]. Another study, using canine
F.VIII cDNA formulated in chitosan, provided transient F.VIII activity that was however
sustainable upon re-administration. No neutralizing F.VIII antibody was detected,
suggesting oral tolerance involvement [194].
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In conclusion, elucidation of the mechanisms of oral tolerance will further facilitate the
success of oral tolerance as a means of controlling or preventing immune responses to
therapeutic proteins. Further investigations are needed in several areas such as the
characterization of therapeutic antigens, modes of antigen processing and presentation,
costimulatory requirements, induction of cytokine responses, and others. In this context,
murine studies may be supplemented with translational studies in large animal models of
disease. As we understand more, we will get closer to effective clinical development of oral
tolerance in treatment of human diseases. For example, targeting pivotal antigen
presentation cells, adding specific adjuvants, co-administration of cytokines such as IL-10 or
TGF-β, optimization of oral antigen delivery, its dosage and feeding frequency, all seem
promising aspects that would greatly improve efficacy of oral tolerance in human disease
therapy.
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Fig. 1. Overview of mechanism of oral tolerance induction
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Oral antigens are sampled by different ways: M cells transfer antigen to DCs by
transcytosis; DCs directly acquire antigen from gut lumen; antigens endotyosized by
enterocytes and DCs or macrophages engulf enterocytes debris containing antigens; antigens
directly cross the epithelial layer. Plasmacytoid or CD11c+ DCs, CD103+ DCs, and CD11b+
DCs are specialized in inducing oral tolerance. DCs get educated in local microenvironment
through local factors and crosstalking with different cell types: intestinal epithelial cells
releasing TGF-β and retinoic acid; lamina propria macrophages producing large amount of
IL-10 and inhibit DCs induction of Th-17 cells; oral immunized memory T cells secrete IL-4
and IL-10 to educate DCs and induce naïve T cells to produce the same cytokines. DCs are
critical in gut hemostasis: DCs from Peyer’s patches and MLN induced B cells to transform
into plasma cells and produce IgA; DCs abrogate a large fraction of antigen-specific CD8+
T cells in liver and MLNs; activated DCs migrate to MLNs and induce Treg. Generally high
dose of oral antigens induce T cell deletion / anergy and low dose antigens induce Treg.
These two mechanisms occur simultaneously and overlap. Apoptotic T cells, macrophages
and DCs that clean up the debris, express high level of TGF-β and suppress inflammatory
cytokines production. Treg suppressed effector T cells responses including inhibition of T
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cell proliferation and blockade of inflammatory cytokines release. TGF-b and IL-10 are high
in gut microenvironment, which is essential for Treg function and maintenance.
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Fig. 2. Example of prevention of a systemic immune response by oral tolerance induction
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Prevention of inhibitory antibody formation and of anaphylactic reactions against
intravenous human F.IX (hF.IX) by oral administration of CTB-hF.IX chloroplast transgenic
plant material in hemophilia B mice. A. Delivery of hF.IX antigen to the GALT. Shown are
Peyer’s patch and villi of ileum of a fed mouse stained for hF.IX (red), M cells (UEA-1,
green), and CD11c (blue). B. Survival of mice fed with wild-type (WT, n= 10 mice at the
onset of protein therapy), CTB-FIX (n=17), or CTB-FFIX (n=15) plant material as a
function of the number of intravenous injections of hF.IX protein (CTB-FFIX contained a
furin cleavage site between the CTB and hF.IX portions of the fusion protein). C. Inhibitor
titers (in BU/ml) at 3-month time point mice (i.e. after 8 weekly IV injections of hF.IX) in
unfed, WT fed, CTB-FIX fed, and CTB-FFIX fed hemophilia B mice. αhis/PAF: titers in
unfed mice that received anti-histamine/anti-PAF prior to a 6th injection of hF.IX to prevent
anaphylaxis. Modified from Proc Natl Acad Sci USA 107(15): 7101-6, 2010; © 2010 by
The National Academy of Sciences of the USA.
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Fig. 3. Mechanisms of Treg induction in oral tolerance
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A. Low dose antigen feeding results in active induction of Treg, which involves cross talk
between different cell types. For example, CD103+ gut DCs are specialized in inducing Treg
via production of retinoic acid (RA), TGF-β, and expression of indoleamine-2,3dioxygenase (IDO). B. High dose oral antigen induces T cell anergy. Anergic T cells
produce cytokines including IL-4, IL-10, TGF-β, and act as suppressor cells to evoke
tolerance. High dose antigen feeding also increases susceptibility to apoptosis. Macrophage
and DC clean up the apoptotic cells and exhibit up-regulation of TGF-β and down regulation
of inflammatory cytokines. Apoptotic cells can also secrete TGF-β, which is critical for
inducing and maintaining Treg. These two mechanisms may occur simultaneously and
overlap as they shared some of the same characteristics such as cytokines production
profiles and generation of induced Treg (iTreg).
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Fig. 4. Induction and multifunction of TGF-β in the gut
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TGF-β is a key cytokine for oral tolerance. Abundant in the gut microenvironment, TGF-β
has multiple functions, including epithelial cell differentiation, IgA class switching, and
induction and maintenance of Foxp3+ Treg. Additionally, TGF-β decreases the
differentiation of naïve T cells into effector Th1 and Th2 cells, drives the development of
TCRαβ+CD8αα+ intestinal intraepithelial lymphocytes (IEL). TGF-β is secreted by a
variety of cells including CD4+, CD8+ T cells, Th3 cells, macrophages, enterocytes, antigenpulsed intestinal epithelial cells (IEC), and gut DCs. Gut DCs produce retinoic acid (RA),
which enhance Foxp3+ Treg induction by TGF-β. In MLN DCs, interaction with Foxp3+
Treg increases expression of indoleamine-2,3-dioxygenase (IDO), which depletes
tryptophan into kynurenines and suppresses effector T cell responses. Besides the secreted
form, an active membrane-bound form (Latency-associated peptide, LAP) exists. Some Treg
express LAP and TGF-β on their cell surface, which is associated with the suppressive
activity of Treg. LAP+ Treg are expanded in oral tolerance.
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Fig. 5. IL-10 expression and function in the gut

IL-10 is a cytokine with broad anti-inflammatory properties and constitutes another key
component in oral tolerance. Highly expressed in the intestine, IL-10 producing cells
increased even more after antigen feeding, especially in Peyer’s patch (PP), lamina propria,
and MLN. Specifically, one regulatory subset of CD4+ T cells mainly producing IL-10,
named Tr1 cells, is induced in oral tolerance. Other regulatory T cells such as Th3. Foxp3+
Treg may also secrete IL-10 and are induced by antigen feeding. Macrophages, B cells, DCs
and CD8+ T cells, epithelial cells, NK cells all have been reported to produce IL-10. IL-10
can be produced by Th2, Th17, and Th1 cells in certain situations, which serves as a
negative feedback loop to limit effector T cell responses, possibly via regulation of antigen
presenting DCs and macrophages. IL-10 is critical for induction of certain subsets of
regulatory T cells and/or their function, which provides a positive regulatory loop for
establishment of oral tolerance.
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cytokine productions.
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Highly expressed in the intestine. Secreted by
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Suppress T cells responses through IL-10.
Induce Foxp3+ Treg.

CD4+ T cells with low proliferative capacity,
high levels of IL-10, and low levels of IL-2,
no IL-4.

Tr1

TGF-β

Antigen presenting to T cells. Gut DCs may
induce Treg, increase T cells expression of
gut homing receptors, and induce B cells
production of IgA.

CD11c+ DCs, CD103+ DCs, and CD11b+
DCs specialize in inducing oral tolerance. Gut
DCs are mainly located in Lamina propria,
Peyer’s patches, MLN.

Dendritic cells

Induces Foxp3 expression

Regulates the expression of adhesion
molecules essential for Treg migration.

Broad anti-inflammatory cytokine. Inhibits
Th1 responses, down-regulates MHC class II
and costimulatory molecules. Important for
Treg induction and function.

Pivotal in epithelial cell differentiation, IgA
class switching, and strong
immunosuppressive effects on lymphocytes.
Induce Treg.

Suppressing an effector T cell response

Take up antigens and effectively transport to
antigen presenting cells

Function

Broad microfolds. Located in Peyer’s patches
and lympho follicles in small intestine

M cells

Characteristics

Key cells, cytokines, and pathways involved in oral tolerance induction

Selective Cox-2 inhibition led to loss of
oral tolerance

Controversial. Some reported that oral
tolerance cannot be induced or adoptive
transferred in IFN-Υ deficient mice.
Others found it did not affect oral
tolerance induction or maintenance.

Antigen feeding induced IL-10 production
and Tr1 cells. IL-10 deficient mice failed
in oral tolerance induction. However,
some reported oral tolerance could be
induced with anti-IL-10 antibody
administration.

Up-regulated in oral tolerance.
Neutralized TGF-β impaired oral
tolerance. TGF-β knockout mice exhibited
no tolerance in low dose feeding and
partial tolerance in high dose feeding.

Population increased in oral tolerance.
Anti-TGF-β antibody reversed the
suppressive effects.

Oral antigen administration induced
Foxp3+ Treg, which transferred tolerance
to naïve recipients.

Oral tolerance decreased Th17 cells

Population increased in orally tolerized
mice and peripheral blood of humans fed
MBP.

Involved in low dose oral tolerance

In vivo expansion of DCs enhances oral
tolerance whereas depletion of DCs
diminished oral tolerance. Adoptive
transfer of MLN pDCs transferred
tolerance.

Targeting M cells using pσ1 conjugation
with antigen enhanced oral tolerance.

Findings in oral tolerance

[126,127]

[121–124]

[80,109,113,115–118]

[90,91,97,98,100,101,103]

[81–83]

[76,77]

[49,195]

[6,79,99]

[74,80,110]

[36,40,41,44,45]

[29,31,32]
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Critical for mucosal DCs function. Regulates
Th17 cell responses. Boost Treg induction.
Transcriptional factor. Pivotal for Treg
functions.

Metabolite of vitamin A. Produced by
mucosal DCs, epithelial cells, MLN stromal
cells, and macrophages.
Mainly expressed in CD4+ T cells. Marker of
Treg.

Retinoic acid

Foxp3

Function

Mutation caused severe autoimmune
disease. Retroviral gene transfer turned
naïve T cells to Treg-like phenotype and
function.

CD103+ DCs in MLN expressed high
level of Aldhla2, which made their own
RA.

Findings in oral tolerance

[142–148,150,151]

[51–53,135–139]
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Hemophi lia A
Hemophi lia B

Pompe disease

Diabetes

Diabetes

Diabetes

Diabetes

Diabetes
Diabetes
Diabetes
Diabetes

F.VIII

F.IX

GAA

Insulin

Insulin

Insulin

Insulin

Insulin

Insulin

Insulin

Insulin

Hemophi lia A

F.VIII

Hemophi lia A

Hemophi lia A

F.VIII

F.VIII C2

Disease

Therape utic protein
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Mice

Mice

Mice

Mice

Mice

Human

Human

Human

Mice

Mice

Mice

Mice

Human

Human

Species

1 mg porcine insulin orally twice a week for 5 weeks,
then weekly until 1 year.

Glutamic acid decarboxylase expressing transgenic
plant as a dietary supplement

Potato expressed CTB-insulin, CTB, or insulin (20 –
30 µg) once per week for 5 weeks

Silkworm produced GFP-CTBinsulin (about 50 µg of
fusion protein) every other day for 5 weeks

Tobacco or lettuce leaves contain CTB-proinsulin
(about 14 µg of fusion protein) or control once a week
for 7 weeks

Oral insulin or placebo treatment of type 1 diabetes
for 1 year

1 or 10 mg insulin tolerance trial in newly diagnosed
diabetic patients with cytoplasmic islet cell
autoantibodies

2.5 or 7.5 mg oral insulin or placebo daily for 1 year
in autoantibody positive patients

16 mg recombinant human GAA 5 times every other
day for 6 days

Tobacco leaves contain CTB-F.IX or CTB-FF.IX
twice per week for 2 months; equivalent to 5–80 µg/
kg recombinant F.IX

1 to 2 µg F.VIII oral gavage neonatal mice every 2 to
3 days for 9 total feedings

Oral or nasal 1–50 µg F.VIII C2 for 5 consecutive
days

20 to 70 U/kg F.VIII oral administrated at intervals
from 1 day to 1 week

1250 IU F.VIII with sodium bicarbonate once daily
for 3 months

Feeding regimen

Reduced lymphocytic infiltration of pancreatic islets; splenic T cells from
orally treated animal adoptively transfer protection against diabetes

Inhibits the development of diabetes in the non-obese diabetic mouse

Only CTB-insulin group showed a reduction in insulitis and a delay in the
diabetes progression, but not insulin or CTB alone group.

Induced special tolerance; delayed the development of diabetic symptoms;
increased the numbers of CD4+CD25+Foxp3+ Treg.

Decreased infiltration of cells characteristics of lymphocytes; insulin
producing β cells were preserved; increased expression of
immunosuppressive cytokines

In oral insulin group, significantly higher TGF-β;markedly reduced IFN-γ;
similar levels of IL-4 and IL-5 in challenged lymphocytes; significantly
lower circulating levels of IgG1 and IgG3 against insulin.

Improved plasma C-peptide responses in patients diagnosed at ages greater
than 20 years, best seen at low (1 mg/daily) over high (10 mg/day) dose.
There were no adverse effects.

No differences were seen in the time course or titers of antibodies to
insulin, glutamic acid decarboxylase or islet antigen 2. Similar insulin
requirements, haemoglobin A1c concentrations, and C peptide
concentrations.

Significantly lower anti-GAA antibody titers; reduced specific IgE against
GAA titers. Not effective with 1 mg and 10 mg oral GAA 3 times every
other day.

Eliminated fatal anaphylactic reactions; blocked formation of inhibitory
antibodies undetectable or up to 100-fold less than controls; controlled
inhibitor formation and anaphylaxis longterm, up to 7 months, about 40%
life span of this mouse strain

No protection against inhibitors formation developed after F.VIII iv
injection.

Decreased the titer of anti-F.VIII C2 inhibitors and antibodies; tolerance
was associated with increased IL-10 and can be adoptively transferred.

Diminished inhibitors titers from 42 BU/ml to 11 BU/ml in one patient;
Inhibitors come back when high dose of prothrombin complex concentrates
was used.

2 of 3 patients had decreased inhibitor titer lasted for 6 months; the other
patients had decreased in vivo proliferation rate of mononucleated cells and
reduced inflammatory cytokines productions

Results
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NIH-PA Author Manuscript

Table 2

[178]

[202]

[201]

[200]

[173]

[199]

[198]

[197]

[169]

[32]

[196]

[172]

[171]

[170]

Reference

Wang et al.
Page 34

Diabetes

Diabetes

Insulin

Insulin
Egg allergy

Diabetes

Insulin

Egg white

Diabetes

Insulin

NIH-PA Author Manuscript
Human

Rat

Mice

Mice

Mice

Species

2 g egg white powder per day for 10 months; 10 g egg
white power till 22 months

0.5 or 1 mg insulin 3 times weekly for 90 days

1 mg equine insulin or ovalbumin twice a week for 5
weeks

600 µg insulin B chain or 250 µg peptide 5
consecutive days, once a week thereafter

0.8 mg human insulin in PBS 3 times a week for 2 – 4
weeks

Feeding regimen

55% in oral-immunotherapy group passed the oral food challenge after 10
months therapy; 75% of children were desensitized in the oralimmunotherapy group at 24 months.

No protection effect was observed in Diabetes prone or Diabetes resistant
BB rats

Considerably less insulitis in insulin fed NOD mice; residual mononuclear
cells expressing IL-4, IL-10, PGE, TGF- β, and an absence of IL-2, IFN-γ
or TNF-α

Slowed diabetes development in a co-transfer model of diabetes in NOD
mouse; a decrease in Th1 cytokine and increase in Th2 cytokines.

Induced insulin B-chain reactive regulatory T cells to block cytokine
secretion and migration of diabetogenic effector T cells
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Therape utic protein

[207]

[206]

[205]

[204]

[203]

Reference

Wang et al.
Page 35

Adv Drug Deliv Rev. Author manuscript; available in PMC 2014 June 15.

